Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck (NYSE:MRK) announced a US$6.7b agreement to acquire Terns Pharmaceuticals. The deal adds Terns' lead investigational oral therapy for chronic myeloid leukemia, TERN-701, to Merck's oncology and hematology pipeline. The acquisition comes as Merck prepares for the planned 2028 patent expiry of its cancer therapy Keytruda. For anyone following large-cap pharma, this deal signals how Merck is positioning its business mix in cancer and blood disorders as Keytruda approaches the end of its exclusivity period. By bringing in Terns' early stage assets, Merck is adding another potential oral therapy in chronic myeloid leukemia, an area where oral treatments are already a key part of care. The move fits with a wider industry focus on targeted therapies and pipeline building through business development. Looking ahead, investors will likely watch how quickly Merck advances TERN-701 through c
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Jim Cramer on Merck & Co.: “If We're Really Going Into an Oil Shock-Induced Slowdown, I Think This One's Likely an Outperformer”” [Yahoo! Finance]Yahoo! Finance
- Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx [Yahoo! Finance]Yahoo! Finance
- Merck's deal for Terns sparks debate over a possible biotech bidding war [Yahoo! Finance]Yahoo! Finance
- RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium” [Yahoo! Finance]Yahoo! Finance
- Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline [MSNBC.com]MSNBC.com
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- MRK's page on the SEC website